O	0	7	Insulin	Insulin	NN	B-NP
O	7	8	-	-	HYPH	O
O	8	15	induced	induce	VBN	B-NP
O	16	24	vascular	vascular	JJ	I-NP
O	25	36	endothelial	endothelial	JJ	I-NP
O	37	43	growth	growth	NN	I-NP
O	44	50	factor	factor	NN	I-NP
O	51	61	expression	expression	NN	I-NP
O	62	64	in	in	IN	B-PP
B-Multi-tissue_structure	65	71	retina	retina	NN	B-NP
O	71	72	.	.	.	O

O	73	80	PURPOSE	PURPOSE	NN	B-NP
O	80	81	:	:	:	O
O	82	90	Clinical	Clinical	JJ	B-NP
O	91	98	studies	study	NNS	I-NP
O	99	103	have	have	VBP	B-VP
O	104	116	demonstrated	demonstrate	VBN	I-VP
O	117	121	that	that	IN	B-SBAR
O	122	131	intensive	intensive	JJ	B-NP
O	132	139	insulin	insulin	NN	I-NP
O	140	147	therapy	therapy	NN	I-NP
O	148	154	causes	cause	VBZ	B-VP
O	155	156	a	a	DT	B-NP
O	157	166	transient	transient	JJ	I-NP
O	167	176	worsening	worsening	NN	I-NP
O	177	179	of	of	IN	B-PP
O	180	191	retinopathy	retinopathy	NN	B-NP
O	191	192	.	.	.	O

O	193	196	The	The	DT	B-NP
O	197	207	mechanisms	mechanism	NNS	I-NP
O	208	218	underlying	underlie	VBG	B-VP
O	219	222	the	the	DT	B-NP
O	223	230	initial	initial	JJ	I-NP
O	231	238	insulin	insulin	NN	I-NP
O	238	239	-	-	HYPH	B-NP
O	239	246	induced	induce	VBN	I-NP
O	247	260	deterioration	deterioration	NN	I-NP
O	261	263	of	of	IN	B-PP
B-Multi-tissue_structure	264	271	retinal	retinal	JJ	B-NP
O	272	278	status	status	NN	I-NP
O	279	281	in	in	IN	B-PP
O	282	290	patients	patient	NNS	B-NP
O	291	295	with	with	IN	B-PP
O	296	304	diabetes	diabete	NNS	B-NP
O	305	311	remain	remain	VBP	B-VP
O	312	319	unknown	unknown	JJ	B-ADJP
O	319	320	.	.	.	O

O	321	329	Vascular	Vascular	JJ	B-NP
O	330	341	endothelial	endothelial	JJ	I-NP
O	342	348	growth	growth	NN	I-NP
O	349	355	factor	factor	NN	I-NP
O	356	357	(	(	(	O
O	357	361	VEGF	VEGF	NN	B-NP
O	361	362	)	)	)	O
O	363	365	is	be	VBZ	B-VP
O	366	371	known	know	VBN	I-VP
O	372	374	to	to	TO	I-VP
O	375	377	be	be	VB	I-VP
O	378	387	operative	operative	JJ	B-ADJP
O	388	390	in	in	IN	B-PP
O	391	394	the	the	DT	B-NP
O	395	407	pathogenesis	pathogenesis	NN	I-NP
O	408	410	of	of	IN	B-PP
O	411	419	diabetic	diabetic	JJ	B-NP
O	420	431	retinopathy	retinopathy	NN	I-NP
O	431	432	.	.	.	O

O	433	436	The	The	DT	B-NP
O	437	444	current	current	JJ	I-NP
O	445	450	study	study	NN	I-NP
O	451	454	was	be	VBD	B-VP
O	455	464	conducted	conduct	VBN	I-VP
O	465	467	to	to	TO	I-VP
O	468	480	characterize	characterize	VB	I-VP
O	481	484	the	the	DT	B-NP
O	485	491	effect	effect	NN	I-NP
O	492	494	of	of	IN	B-PP
O	495	502	insulin	insulin	NN	B-NP
O	503	505	on	on	IN	B-PP
B-Multi-tissue_structure	506	513	retinal	retinal	JJ	B-NP
O	514	518	VEGF	VEGF	NN	I-NP
O	519	523	gene	gene	NN	I-NP
O	524	534	expression	expression	NN	I-NP
O	535	537	in	in	FW	B-ADVP
O	538	543	vitro	vitro	FW	I-ADVP
O	544	547	and	and	CC	O
O	548	550	in	in	FW	B-ADVP
O	551	555	vivo	vivo	FW	I-ADVP
O	555	556	.	.	.	O

O	557	564	METHODS	METHODS	NNS	B-NP
O	564	565	:	:	:	O
O	566	569	The	The	DT	B-NP
O	570	576	effect	effect	NN	I-NP
O	577	579	of	of	IN	B-PP
O	580	587	insulin	insulin	NN	B-NP
O	588	590	on	on	IN	B-PP
O	591	595	VEGF	VEGF	NN	B-NP
O	596	606	expression	expression	NN	I-NP
O	607	609	in	in	FW	B-ADVP
O	610	614	vivo	vivo	FW	I-ADVP
O	615	618	was	be	VBD	B-VP
O	619	627	examined	examine	VBN	I-VP
O	628	630	by	by	IN	B-PP
O	631	633	in	in	FW	B-NP
O	634	638	situ	situ	FW	I-NP
O	639	652	hybridization	hybridization	NN	I-NP
O	653	660	studies	study	NNS	I-NP
O	661	663	of	of	IN	B-PP
O	664	667	rat	rat	NN	B-NP
B-Multi-tissue_structure	668	675	retinal	retinal	JJ	I-NP
O	676	680	VEGF	VEGF	NN	I-NP
O	681	692	transcripts	transcript	NNS	I-NP
O	692	693	.	.	.	O

O	694	696	To	To	TO	B-VP
O	697	704	examine	examine	VB	I-VP
O	705	708	the	the	DT	B-NP
O	709	719	mechanisms	mechanism	NNS	I-NP
O	720	722	by	by	IN	B-PP
O	723	728	which	which	WDT	B-NP
O	729	736	insulin	insulin	NN	B-NP
O	737	746	regulates	regulate	VBZ	B-VP
O	747	751	VEGF	VEGF	NN	B-NP
O	752	762	expression	expression	NN	I-NP
O	762	763	,	,	,	O
O	764	769	human	human	JJ	B-NP
B-Cell	770	777	retinal	retinal	JJ	I-NP
I-Cell	778	785	pigment	pigment	NN	I-NP
I-Cell	786	796	epithelial	epithelial	JJ	B-ADJP
I-Cell	797	798	(	(	(	O
I-Cell	798	801	RPE	RPE	NN	B-NP
I-Cell	801	802	)	)	)	I-NP
I-Cell	803	808	cells	cell	NNS	I-NP
O	809	813	were	be	VBD	B-VP
O	814	821	exposed	expose	VBN	I-VP
O	822	824	to	to	TO	B-PP
O	825	832	insulin	insulin	NN	B-NP
O	832	833	,	,	,	O
O	834	837	and	and	CC	O
O	838	842	VEGF	VEGF	NN	B-NP
O	843	847	mRNA	mRNA	NN	I-NP
O	848	854	levels	level	NNS	I-NP
O	855	859	were	be	VBD	B-VP
O	860	870	quantified	quantify	VBN	I-VP
O	871	875	with	with	IN	B-PP
O	876	881	RNase	RNase	NN	B-NP
O	882	892	protection	protection	NN	I-NP
O	893	899	assays	assay	NNS	I-NP
O	900	901	(	(	(	O
O	901	905	RPAs	RPA	NNS	B-NP
O	905	906	)	)	)	O
O	906	907	.	.	.	O

O	908	919	Conditioned	Condition	VBN	B-NP
O	920	925	media	medium	NNS	I-NP
O	926	930	from	from	IN	B-PP
O	931	938	insulin	insulin	NN	B-NP
O	938	939	-	-	HYPH	B-NP
O	939	946	treated	treat	VBN	I-NP
B-Cell	947	950	RPE	RPE	NN	I-NP
I-Cell	951	956	cells	cell	NNS	I-NP
O	957	961	were	be	VBD	B-VP
O	962	969	assayed	assay	VBN	I-VP
O	970	973	for	for	IN	B-PP
O	974	978	VEGF	VEGF	NN	B-NP
O	979	986	protein	protein	NN	I-NP
O	987	990	and	and	CC	O
B-Cell	991	1000	capillary	capillary	JJ	B-NP
I-Cell	1001	1012	endothelial	endothelial	JJ	I-NP
I-Cell	1013	1017	cell	cell	NN	I-NP
O	1018	1031	proliferation	proliferation	NN	I-NP
O	1031	1032	.	.	.	O

O	1033	1036	The	The	DT	B-NP
O	1037	1045	capacity	capacity	NN	I-NP
O	1046	1048	of	of	IN	B-PP
O	1049	1056	insulin	insulin	NN	B-NP
O	1057	1059	to	to	TO	B-VP
O	1060	1069	stimulate	stimulate	VB	I-VP
O	1070	1073	the	the	DT	B-NP
O	1074	1078	VEGF	VEGF	NN	I-NP
O	1079	1087	promoter	promoter	NN	I-NP
O	1088	1094	linked	link	VBN	B-VP
O	1095	1097	to	to	TO	B-PP
O	1098	1099	a	a	DT	B-NP
O	1100	1110	luciferase	luciferase	NN	I-NP
O	1111	1119	reporter	reporter	NN	I-NP
O	1120	1124	gene	gene	NN	I-NP
O	1125	1128	was	be	VBD	B-VP
O	1129	1142	characterized	characterize	VBN	I-VP
O	1143	1145	in	in	IN	B-PP
O	1146	1155	transient	transient	JJ	B-NP
O	1156	1168	transfection	transfection	NN	I-NP
O	1169	1175	assays	assay	NNS	I-NP
O	1175	1176	.	.	.	O

O	1177	1184	RESULTS	RESULTS	NNS	B-NP
O	1184	1185	:	:	:	O
O	1186	1193	Insulin	Insulin	NN	B-NP
O	1194	1203	increased	increase	VBD	B-VP
O	1204	1208	VEGF	VEGF	NN	B-NP
O	1209	1213	mRNA	mRNA	NN	I-NP
O	1214	1220	levels	level	NNS	I-NP
O	1221	1223	in	in	IN	B-PP
O	1224	1227	the	the	DT	B-NP
B-Tissue	1228	1236	ganglion	ganglion	NN	I-NP
O	1236	1237	,	,	,	O
B-Tissue	1238	1243	inner	inner	JJ	B-NP
I-Tissue	1244	1251	nuclear	nuclear	JJ	I-NP
O	1251	1252	,	,	,	O
O	1253	1256	and	and	CC	O
B-Tissue	1257	1260	RPE	RPE	NN	B-NP
I-Tissue	1261	1265	cell	cell	NN	I-NP
I-Tissue	1266	1272	layers	layer	NNS	I-NP
O	1272	1273	.	.	.	O

O	1274	1276	In	In	FW	B-ADVP
O	1277	1282	vitro	vitro	FW	I-ADVP
O	1282	1283	,	,	,	O
O	1284	1291	insulin	insulin	NN	B-NP
O	1292	1301	increased	increase	VBD	B-VP
O	1302	1306	VEGF	VEGF	NN	B-NP
O	1307	1311	mRNA	mRNA	NN	I-NP
O	1312	1318	levels	level	NNS	I-NP
O	1319	1321	in	in	IN	B-PP
O	1322	1327	human	human	JJ	B-NP
B-Cell	1328	1331	RPE	RPE	NN	I-NP
I-Cell	1332	1337	cells	cell	NNS	I-NP
O	1338	1341	and	and	CC	O
O	1342	1350	enhanced	enhance	VBN	B-NP
O	1351	1355	VEGF	VEGF	NN	I-NP
O	1356	1364	promoter	promoter	NN	I-NP
O	1365	1373	activity	activity	NN	I-NP
O	1374	1381	without	without	IN	B-PP
O	1382	1391	affecting	affect	VBG	B-VP
O	1392	1402	transcript	transcript	NN	B-NP
O	1403	1412	stability	stability	NN	I-NP
O	1412	1413	.	.	.	O

O	1414	1421	Insulin	Insulin	NN	B-NP
O	1422	1431	treatment	treatment	NN	I-NP
O	1432	1436	also	also	RB	B-ADVP
O	1437	1446	increased	increase	VBD	B-VP
O	1447	1451	VEGF	VEGF	NN	B-NP
O	1452	1459	protein	protein	NN	I-NP
O	1460	1466	levels	level	NNS	I-NP
O	1467	1469	in	in	IN	B-PP
O	1470	1481	conditioned	condition	VBN	B-NP
B-Cell	1482	1485	RPE	RPE	NN	I-NP
I-Cell	1486	1490	cell	cell	NN	I-NP
O	1491	1496	media	medium	NNS	I-NP
O	1497	1499	in	in	IN	B-PP
O	1500	1501	a	a	DT	B-NP
O	1502	1506	dose	dose	NN	I-NP
O	1506	1507	-	-	HYPH	B-NP
O	1507	1516	dependent	dependent	JJ	I-NP
O	1517	1523	manner	manner	NN	I-NP
O	1524	1528	with	with	IN	B-PP
O	1529	1530	a	a	DT	B-NP
O	1531	1537	median	median	JJ	I-NP
O	1538	1547	effective	effective	JJ	I-NP
O	1548	1561	concentration	concentration	NN	I-NP
O	1562	1564	of	of	IN	B-PP
O	1565	1566	5	5	CD	B-NP
O	1567	1569	nM	nM	NN	I-NP
O	1569	1570	.	.	.	O

O	1571	1574	The	The	DT	B-NP
O	1575	1582	insulin	insulin	NN	I-NP
O	1582	1583	-	-	HYPH	B-VP
O	1583	1594	conditioned	condition	VBN	B-NP
B-Cell	1595	1598	RPE	RPE	NN	I-NP
I-Cell	1599	1603	cell	cell	NN	I-NP
O	1604	1609	media	medium	NNS	I-NP
O	1610	1620	stimulated	stimulate	VBD	B-VP
B-Cell	1621	1630	capillary	capillary	JJ	B-NP
I-Cell	1631	1642	endothelial	endothelial	JJ	I-NP
I-Cell	1643	1647	cell	cell	NN	I-NP
O	1648	1661	proliferation	proliferation	NN	I-NP
O	1661	1662	,	,	,	O
O	1663	1665	an	an	DT	B-NP
O	1666	1672	effect	effect	NN	I-NP
O	1673	1677	that	that	WDT	B-NP
O	1678	1681	was	be	VBD	B-VP
O	1682	1692	completely	completely	RB	I-VP
O	1693	1700	blocked	block	VBN	I-VP
O	1701	1703	by	by	IN	B-PP
O	1704	1708	anti	anti	AFX	B-NP
O	1708	1709	-	-	HYPH	I-NP
O	1709	1713	VEGF	VEGF	NN	B-NP
O	1714	1726	neutralizing	neutralize	VBG	B-VP
O	1727	1735	antibody	antibody	NN	B-NP
O	1735	1736	.	.	.	O

O	1737	1748	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1748	1749	:	:	:	O
O	1750	1757	Insulin	Insulin	NN	B-NP
O	1758	1767	increases	increase	VBZ	B-VP
O	1768	1772	VEGF	VEGF	NN	B-NP
O	1773	1777	mRNA	mRNA	NN	I-NP
O	1778	1781	and	and	CC	O
O	1782	1790	secreted	secrete	VBN	B-NP
O	1791	1798	protein	protein	NN	I-NP
O	1799	1805	levels	level	NNS	I-NP
O	1806	1808	in	in	IN	B-PP
B-Cell	1809	1812	RPE	RPE	NN	B-NP
I-Cell	1813	1818	cells	cell	NNS	I-NP
O	1819	1826	through	through	IN	B-PP
O	1827	1835	enhanced	enhance	VBN	B-NP
O	1836	1849	transcription	transcription	NN	I-NP
O	1850	1852	of	of	IN	B-PP
O	1853	1856	the	the	DT	B-NP
O	1857	1861	VEGF	VEGF	NN	I-NP
O	1862	1866	gene	gene	NN	I-NP
O	1866	1867	.	.	.	O

O	1868	1877	Intensive	Intensive	JJ	B-NP
O	1878	1885	insulin	insulin	NN	I-NP
O	1886	1893	therapy	therapy	NN	I-NP
O	1894	1897	may	may	MD	B-VP
O	1898	1903	cause	cause	VB	I-VP
O	1904	1905	a	a	DT	B-NP
O	1906	1915	transient	transient	JJ	I-NP
O	1916	1925	worsening	worsening	NN	I-NP
O	1926	1928	of	of	IN	B-PP
O	1929	1940	retinopathy	retinopathy	NN	B-NP
O	1941	1943	in	in	IN	B-PP
O	1944	1952	patients	patient	NNS	B-NP
O	1953	1957	with	with	IN	B-PP
O	1958	1966	diabetes	diabetes	NN	B-NP
O	1967	1974	through	through	IN	B-PP
O	1975	1984	increased	increase	VBN	B-NP
B-Multi-tissue_structure	1985	1992	retinal	retinal	JJ	I-NP
O	1993	1997	VEGF	VEGF	NN	I-NP
O	1998	2002	gene	gene	NN	I-NP
O	2003	2013	expression	expression	NN	I-NP
O	2013	2014	.	.	.	O

